Production (Stage)
United Therapeutics Corporation
UTHR
$307.65
-$1.07-0.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.94% | -2.52% | 11.15% | -9.30% | 41.23% |
| Total Depreciation and Amortization | 0.51% | 3.14% | 2.14% | 24.67% | 9.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.85% | -32.22% | -18.55% | 192.72% | 30.17% |
| Change in Net Operating Assets | 1,957.14% | -132.31% | 111.95% | -373.37% | 143.40% |
| Cash from Operations | 35.17% | -9.54% | 62.45% | -38.33% | 149.83% |
| Capital Expenditure | 13.61% | -13.33% | -69.62% | -18.06% | 51.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -146.03% | 4.95% | -10.03% | -104.51% | 268.33% |
| Cash from Investing | -33.69% | -7.22% | -43.63% | -110.88% | 1,646.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -16.02% | -29.48% | -30.33% | 13.02% | 531.51% |
| Repurchase of Common Stock | -5,000.00% | 25.00% | -300.00% | 99.99% | -1,011,300.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -25.57% | -16.54% | -33.54% | 95.51% | -1,050.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.45% | -27.70% | 90.21% | 137.90% | -56.20% |